Hangzhou Tigermed Consulting Co., Ltd (HKG:3347)
30.35
+0.10 (0.33%)
Apr 3, 2025, 4:08 PM HKT
HKG:3347 Revenue
In the year 2024, Hangzhou Tigermed Consulting had annual revenue of 6.60B CNY, down -10.58%. Hangzhou Tigermed Consulting had revenue of 1.54B in the quarter ending December 31, 2024, a decrease of -11.42%.
Revenue
6.60B CNY
Revenue Growth
-10.58%
P/S Ratio
n/a
Revenue / Employee
680.66K CNY
Employees
9,701
Market Cap
43.64B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 6.60B | -780.92M | -10.58% |
Dec 31, 2023 | 7.38B | 298.57M | 4.21% |
Jan 1, 2023 | 7.09B | 1.87B | 35.91% |
Jan 1, 2022 | 5.21B | 2.02B | 63.32% |
Dec 31, 2020 | 3.19B | 388.97M | 13.88% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 29.60B |
Hansoh Pharmaceutical Group Company | 13.05B |
WuXi Biologics | 19.87B |
JD Health International | 61.89B |
Innovent Biologics | 10.03B |
Akeso | 2.26B |
Alibaba Health Information Technology | 31.39B |
Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |